CareDx, Inc. (CDNA): Price and Financial Metrics

CareDx, Inc. (CDNA): $12.55

0.49 (+4.06%)

POWR Rating

Component Grades














  • CDNA scores best on the Value dimension, with a Value rank ahead of 81.16% of US stocks.
  • The strongest trend for CDNA is in Stability, which has been heading up over the past 179 days.
  • CDNA ranks lowest in Momentum; there it ranks in the 1st percentile.

CDNA Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.22 for CAREDX INC; that's greater than it is for merely 14.05% of US stocks.
  • With a year-over-year growth in debt of 94.16%, CAREDX INC's debt growth rate surpasses 87.61% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, CAREDX INC is reporting a growth rate of 305.58%; that's higher than 94.51% of US stocks.
  • Stocks that are quantitatively similar to CDNA, based on their financial statements, market capitalization, and price volatility, are VMEO, DMRC, CASI, LNSR, and MKFG.
  • CDNA's SEC filings can be seen here. And to visit CAREDX INC's official web site, go to

CDNA Valuation Summary

  • In comparison to the median Healthcare stock, CDNA's price/sales ratio is 56.25% lower, now standing at 2.1.
  • Over the past 102 months, CDNA's price/sales ratio has gone down 2.2.

Below are key valuation metrics over time for CDNA.

Stock Date P/S P/B P/E EV/EBIT
CDNA 2022-11-25 2.1 1.6 -9.2 -8.3
CDNA 2022-11-23 2.1 1.6 -9.1 -8.2
CDNA 2022-11-22 2.1 1.5 -8.9 -8.0
CDNA 2022-11-21 2.1 1.5 -9.0 -8.0
CDNA 2022-11-18 2.2 1.6 -9.2 -8.3
CDNA 2022-11-17 2.4 1.8 -10.5 -9.5

CDNA Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 86.39%.
  • The 4 year net cashflow from operations growth rate now stands at 100.26%.
  • Its 4 year revenue growth rate is now at 243.25%.
Over the past 52 months, CDNA's revenue has gone up $262,059,000.

The table below shows CDNA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 318.629 -28.258 -74.435
2022-06-30 314.859 -20.797 -69.393
2022-03-31 308.413 -7.132 -49.623
2021-12-31 296.397 -19.294 -30.662
2021-09-30 275.821 -16.279 -18.026
2021-06-30 253.601 -11.454 -8.947

CDNA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDNA has a Quality Grade of C, ranking ahead of 63.01% of graded US stocks.
  • CDNA's asset turnover comes in at 0.543 -- ranking 49th of 81 Healthcare stocks.
  • MGLN, OPGN, and LH are the stocks whose asset turnover ratios are most correlated with CDNA.

The table below shows CDNA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.543 0.676 -0.174
2021-06-30 0.557 0.680 -0.105
2021-03-31 0.550 0.673 -0.201
2020-12-31 0.628 0.672 -0.382
2020-09-30 0.673 0.664 -0.802
2020-06-30 0.751 0.655 -1.009

CDNA Price Target

For more insight on analysts targets of CDNA, see our CDNA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $107.33 Average Broker Recommendation 1.36 (Strong Buy)

CDNA Stock Price Chart Interactive Chart >

Price chart for CDNA

CDNA Price/Volume Stats

Current price $12.55 52-week high $47.82
Prev. close $12.06 52-week low $11.92
Day low $11.99 Volume 412,379
Day high $12.80 Avg. volume 836,650
50-day MA $16.22 Dividend yield N/A
200-day MA $24.75 Market Cap 671.89M

CareDx, Inc. (CDNA) Company Bio

CareDx, Inc. focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is based in Brisbane, California.

CDNA Latest News Stream

Event/Time News Detail
Loading, please wait...

CDNA Latest Social Stream

Loading social stream, please wait...

View Full CDNA Social Stream

Latest CDNA News From Around the Web

Below are the latest news stories about CAREDX INC that investors may wish to consider to help them evaluate CDNA as an investment opportunity.

Here's Why CareDx (CDNA) Could be Great Choice for a Bottom Fisher

CareDx (CDNA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Yahoo | November 17, 2022

CareDx (CDNA) Loses 22.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

CareDx (CDNA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | November 11, 2022

CareDx Committed to Delivering Clinical Innovation to the Transplant Patient and Physician Community

BRISBANE, Calif., November 11, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the five-year anniversary of AlloSure®, the groundbreaking, non-invasive donor-derived cell-free DNA (dd-cfDNA) surveillance solution used to measure allograft injury in solid organ transplant recipients. AlloSure along with Allo

Yahoo | November 11, 2022

Analysts Have Been Trimming Their CareDx, Inc (NASDAQ:CDNA) Price Target After Its Latest Report

It's been a mediocre week for CareDx, Inc ( NASDAQ:CDNA ) shareholders, with the stock dropping 19% to US$16.02 in the...

Yahoo | November 6, 2022

CareDx To Participate in Upcoming Investor Conferences

BRISBANE, Calif., November 04, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences.

Yahoo | November 4, 2022

Read More 'CDNA' Stories Here

CDNA Price Returns

1-mo -36.97%
3-mo -38.21%
6-mo -51.62%
1-year -70.91%
3-year -38.84%
5-year 76.26%
YTD -72.41%
2021 -37.23%
2020 235.88%
2019 -14.20%
2018 242.51%
2017 171.85%

Continue Researching CDNA

Want to see what other sources are saying about CareDx Inc's financials and stock price? Try the links below:

CareDx Inc (CDNA) Stock Price | Nasdaq
CareDx Inc (CDNA) Stock Quote, History and News - Yahoo Finance
CareDx Inc (CDNA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8485 seconds.